In one of the early studies evaluating the impact of 68Ga-labeled Bombesin antagonists in prostate cancer, the authors observed a significant difference in SUV between cancerous and hyperplastic prostatic lesions [18]. This evidence concerns the gene GRP and prostate cancer.